Navigation Links
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date:12/9/2009

atory clinical trial will be required to establish efficacy and safety of the product for marketing authorization purposes. Helix intends to continue to make preparations to conduct a European Phase III trial for this purpose, although the timing of filing the European Phase III CTA has not yet been established. The timing of both the planned U.S. and European trials will be contingent on the timing of regulatory approvals of the trials as well as obtaining additional capital.
  • Enrollment in the ongoing Phase II clinical trial in patients with anogenital warts ("AGW") in Sweden and Germany was completed subsequent to the Company's first quarter of fiscal 2010.
  • Financing

    • Completed a private placement financing on September 8, 2009 for gross proceeds of $13,581,250.
    • Prof. Majewski, stepped down from the Board of Directors to assume the advisory role of European medical director, effective August 11, 2009.
    • Prof. Kazimierz Roszkowski-Sliz was appointed to the Board of Directors on August 17, 2009.

    FINANCIAL REVIEW

    During the first quarter of fiscal 2010, the Company recorded a loss of $3,473,000 or $0.06 per common share, resulting in a higher loss of $1,152,000 when compared to the first quarter of fiscal 2009. The Company recorded a loss of $2,321,000, or $0.05 per common share in the first quarter of fiscal 2009.

    Revenues in the first quarter of fiscal 2010 totalled $1,020,000 (2009 - $1,119,000), resulting in a decrease of $99,000 or 8.8% when compared to the first quarter of fiscal 2009.

    Product revenues totalled $903,000 in the first quarter of fiscal 2010 and represents 88.5% of total revenues. When compared to the first quarter of fiscal 2009, product revenues decreased by $18,000 or 2.0%. Sales of both Klean-Prep® and Imunovir® were marginally higher in the quarter, however these were offset by the net decrease in combined
    '/>"/>

    SOURCE Helix BioPharma Corp.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
    2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
    3. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
    4. Helix BioPharma Corp. Announces Fiscal 2009 Results
    5. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
    6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
    10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
    11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... Research and Markets  has announced the ... Product, End-user & by Lead Type - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The global ... segments, namely, holter monitor, resting, and stress type diagnostic ... million in 2013 and is poised to grow at ...
    (Date:7/23/2014)... -- RT Oncology Services Corporation today announced that Craig ... directors. Mr. Mundie is currently senior advisor to the ... projects within the company and on technology strategy and ... officer. Mike Martin , president ... a visionary technology executive. His appointment is part of ...
    (Date:7/23/2014)... July 23, 2014  Nonin Medical, Inc., the inventor ... medical monitoring, announced today that Mark VanderWerf , ... elected Chairman of the American Telemedicine Association,s (ATA) Industry ... The ATA is the leading international resource ... technologies. The ATA and its diverse membership work to ...
    Breaking Medicine Technology:Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3Nonin Medical Announces that Mark VanderWerf has been Elected Chairman of the American Telemedicine Association's Industry Council 2
    ... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
    ... 31, 2011 Nephros, Inc. (OTC Bulletin Board: ... marketing filtration products for therapeutic applications, infection control, and ... Form S-1 for its previously announced rights offering to ... 2011 by the Securities and Exchange Commission. ...
    Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
    (Date:7/23/2014)... 23, 2014 The American Telemedicine ... ATA’s twentieth annual meeting and tradeshow focused exclusively ... to attract over 5,000 attendees and more than ... May 3-5, 2015, in Los Angeles. , ATA’s ... technology professionals from researchers, clinicians, hospital and university ...
    (Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
    (Date:7/23/2014)... not be the sole domain of humans, with new ... comes to the love of their master. When ... stuffed dog, the real puppies in the study responded ... researchers from the University of California, San Diego (UCSD). ... attending to the stuffed dog and not when they ...
    (Date:7/23/2014)... research on human cancer genes have been focused on ... to be translated in the form of amino acids ... a regulatory region or activator which controls the expression ... little was known of the role exerted such DNA ... today in Nature in collaboration with the ...
    (Date:7/23/2014)... (PRWEB) July 23, 2014 CarePoint Health ... first hospital in New Jersey to receive the da ... robotics platform in the da Vinci series. This 4th ... profound step forward in innovation. The intuitive da Vinci ... a wide spectrum of minimally invasive and complex surgical ...
    Breaking Medicine News(10 mins):Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Dogs Can Get Jealous, Too 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4
    ... to provide guidance for global market development.SUNNYVALE, Calif. ... Systems, Inc., a technology leader in developing novel ... of Hironori Yamamoto, MD, PhD, of Jichi Medical ... privileged that Dr. Yamamoto has elected to join ...
    ... Other Health Insurers Are Illegally Denying Treatment to Autistic ... being released by Consumer Watchdog: Who: Guillermo Arce , ... father of Frank Nagle , Harvey Rosenfield ... insurance reform initiative, Proposition 103 , Scott Glovsky ...
    ... how autoimmune diseases are triggered , , TUESDAY, Feb. ... by exposure to pig brains might help researchers learn ... More than a year ago, workers at pork processing ... and tingling in their arms and legs. Their common ...
    ... MDVN ) today announced that it will ... on Wednesday, February 25, at 4:30 p.m. Eastern Time ... ongoing Phase 1-2 clinical trial of the Company,s novel ... Scher, M.D., principal investigator of the trial and chief ...
    ... TrinityCare Senior Living, Inc. (formerly OTCBB: JKAN) (the ... facilities, today announced that its Board of Directors has ... the public entity from July 31st to December 31st. ... and re-incorporation was completed and approved on February 16, ...
    ... HARRISBURG, Pa., Feb. 24 Swiss Villa Dairy Farm ... monocytogenes contamination and resumed sales of raw milk on ... milk is milk that has not been pasteurized. ... have samples of their milk laboratory tested due to ...
    Cached Medicine News:Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 2Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 3Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 4Health News:Parents of Autistic Children Fight Back - Warn HMO Regulator Against Changing Rules to Favor Insurers That Deny Access to Medical Treatment 2Health News:Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients 2Health News:TrinityCare Senior Living, Inc. Changes Fiscal Year End to December 31st 2
    ... manufacturers focus attention on implant design, one ... Profix Total Knee System seeks to establish ... system and the tools to implant them. ... recognized for innovation in total knee instrumentation, ...
    The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The implant is available in three sizes, each of which can be combined with the next size up or down....
    Cementless hip system...
    ... knee system was designed to ... between all articulating surfaces and ... with wear in order to ... with normalized quadriceps and patellar ...
    Medicine Products: